EHPM Botanicals Working Group Chair Profile: Implications for Supplement Manufacturers
Jonathan Griffith, a seasoned expert in European regulatory affairs, chairs EHPM's botanicals working group. His extensive background in wholesaling regulations and health product distribution is highly relevant for supplement manufacturers and brand owners navigating the complex EU market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
In the intricate landscape of European supplement regulation, the expertise of figures within organisations like the European Health Product Manufacturers (EHPM) is paramount. Jonathan Griffith, whose profile highlights a career deeply entwined with the health product industry, currently chairs EHPM’s botanicals working group. This role holds significant implications for supplement manufacturers and brand owners, especially those operating within or looking to enter the European Union market.
Mr. Griffith’s background is notably comprehensive. As Managing Director and Quality Assurance Manager of Natural Medicine Company Limited, a licensed pharmaceutical wholesaler in Ireland, he possesses direct operational experience in product distribution. This isn't merely academic; it's hands-on knowledge of how health products move from production to market, subject to rigorous quality and regulatory controls. For manufacturers like us at Supplement Factory, understanding the perspectives of individuals with this level of practical insight is crucial as we advise our clients on navigating the complexities of the supply chain and ensuring GMP compliance.
Regulatory Acumen and Industry Influence
His tenure as a founding member and General Secretary of the Irish Health Product Manufacturers Association (now the Irish Health Trade Association) between 1986 and 1998, followed by a vice-chairman role on the EHPM Board from 2002 to 2006, underscores a long-standing commitment to industry advocacy and standard-setting. This institutional memory and deep engagement provide a unique lens through which the future of botanicals regulation might be viewed.
Furthermore, his involvement with the European Scientific Co-Operative for Phytotherapy (ESCOP) as an Irish delegate for nearly two decades highlights a strong focus on the scientific substantiation of herbal products. From a formulation standpoint, this signifies that discussions around acceptable botanical extracts, their permitted claims, and safety profiles within the EU are likely to be informed by a blend of scientific evidence and practical regulatory applicability. Brand owners developing botanical-rich supplements should pay close attention to any guidance or best practices emerging from such groups, as they often foreshadow changes in national and EU-level enforcement.
“His specific expertise in the regulations governing the wholesaling of food, cosmetic, and medicinal products in the European Union is particularly relevant to our sector. It covers the full spectrum of products that often blur lines in ingredient use and regulatory oversight,” notes a Supplement Factory internal regulatory expert.
The role of his working group in EHPM is to shape the narrative and influence policy around botanicals, which form a significant segment of the wellness market. For contract manufacturers, this means being prepared to adapt formulations, sourcing strategies, and labelling practices in anticipation of evolving regulatory interpretations and harmonisation efforts across member states. Staying abreast of the insights and directions championed by leaders such as Jonathan Griffith is not just good practice; it’s essential for strategic planning and success in the dynamic European supplement industry.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.